Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2016-07-01 Capital/Financing Update
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2016
Capital/Financing Update Classification · 95% confidence The document is a formal announcement dated July 1, 2016, detailing several key corporate updates: delays in capital raising, changes to a property development plan (Portinho), adjustments to the Russian investment strategy, the initiation of a share buyback program (up to 2% of shares), and a change in the Board of Directors (one member resigning). These updates concern financing, capital structure, and management changes, but they are presented as a formal update/correction rather than a full periodic report (like 10-K or IR). The content strongly aligns with announcements regarding capital structure changes (share buyback) and management changes (Board resignation). Since it covers multiple strategic and capital-related updates, it fits best under Capital/Financing Update (CAP) due to the significant focus on capital raising delays and the share buyback program, or potentially Management Information (MANG) due to the board change. However, the primary focus seems to be on financial strategy adjustments and capital activities. Given the explicit mention of initiating a share buyback program ('Opkøb af egne aktier') and the detailed discussion on capital raising challenges, 'CAP' (Capital/Financing Update) is the most appropriate primary classification, although 'MANG' is also relevant due to the board change. Since the document is a comprehensive update covering multiple strategic areas, and not just a simple announcement of a report, it is not RPA or RNS. I will classify it as CAP as the financing/capital aspect is heavily emphasized.
2016-07-01 English
Regulatory Filings 2016
Regulatory Filings Classification · 99% confidence The document text is a formal announcement from Blue Vision A/S detailing several key corporate updates: delays in capital raising, plans to start construction on the Portinho project, adjustments to the Russian investment strategy, an intention to launch a share buyback program (up to 2% of shares), and a change in the composition of the Board of Directors (one member resigning due to a job change). These updates are presented as a summary of recent developments and future plans, often referencing previous company announcements ('selskabsmeddelelse'). The content strongly aligns with the scope of a Management Report (MDA), which typically includes management's explanation of business trends, outlook, and significant operational/strategic changes that are not strictly financial results (ER) or formal regulatory filings (10-K/IR). While it touches upon financing (CAP) and share transactions (POS), the document serves as a comprehensive update from management on multiple fronts.
2016-07-01 Danish
Delårsrapportering 1. kvartal 2016
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Delårsrapportering 1. kvartal 2016' (Interim Report Q1 2016) and contains substantive financial data, including profit/loss figures and equity values for the period. Although it is relatively short, it provides the actual financial results rather than just announcing the availability of a separate report. Therefore, it qualifies as an Interim/Quarterly Report (IR). Q1 2016
2016-05-12 English
Delårsrapportering 1. kvartal 2016
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Blue Vision A/S covering the period from January 1 to March 31, 2016. It contains comprehensive financial statements, including the income statement, balance sheet, cash flow statement, and management commentary. It is not an announcement of a report, but the report itself, and it contains substantive financial data, fitting the definition of an Interim/Quarterly Report. Q1 2016
2016-05-12 English
Delårsrapportering 1. kvartal 2016
Interim / Quarterly Report Classification · 85% confidence The document is a ‘delårsrapport’ (interim report) approved by the board for the period January 1–March 31, 2016. It provides summary financial results (profit after tax, equity), key operational highlights for Q1, and events after period end. It is not merely an announcement that the report has been published, nor is it a short earnings press release only listing top‐line metrics. Instead, it contains substantive interim financial data and analysis for the quarter, matching the definition of an Interim/Quarterly Report (IR). Q1 2016
2016-05-12 Danish
Share Issue/Capital Change 2016
Share Issue/Capital Change Classification · 99% confidence The document is a formal announcement from Blue Vision A/S, dated May 9, 2016, titled "Rettet emission - konkretisering" (Corrected issuance - concretization). It refers to previous announcements regarding raising capital (DKK 60 million) for an acquisition strategy. Crucially, it states that the intended method of capital raising is changing from issuing new B-shares to issuing convertible bonds ('udstedelse af konvertible obligationer'). This directly relates to financing activities and changes in the capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (1324 chars), but it is the primary announcement detailing the financing structure change, not just announcing that a report is available.
2016-05-09 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.